230 related articles for article (PubMed ID: 11524770)
41. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
42. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia.
von Wussow P; Freund M; Dahle S; Jakschies D; Poliwode H; Deicher H
N Engl J Med; 1988 Nov; 319(18):1226-7. PubMed ID: 2459619
[No Abstract] [Full Text] [Related]
43. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
44. The role of alpha-interferon in chronic myelogenous leukaemia in Imatinib era.
Franceschini R; Zoppi F; Garuti A; Gobbi M
J Exp Clin Cancer Res; 2004 Dec; 23(4):697-8. PubMed ID: 15743042
[No Abstract] [Full Text] [Related]
45. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
46. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Clin Transplant; 2006; 20(1):127-31. PubMed ID: 16556167
[TBL] [Abstract][Full Text] [Related]
47. [Blood diseases].
Bottura C
Prensa Med Argent; 1966 Sep; 53(39):2358-69. PubMed ID: 4969976
[No Abstract] [Full Text] [Related]
48. New drugs for the treatment of lymphoma.
Paoluzzi L; Kitagawa Y; Kalac M; Zain J; O'Connor OA
Hematol Oncol Clin North Am; 2008 Oct; 22(5):1007-35, x. PubMed ID: 18954749
[TBL] [Abstract][Full Text] [Related]
49. [Interferons].
Dicato M
Bull Soc Sci Med Grand Duche Luxemb; 1980; 117(2):29-31. PubMed ID: 6169463
[No Abstract] [Full Text] [Related]
50. Interferon.
Hood LE
Am J Nurs; 1987 Apr; 87(4):459-65. PubMed ID: 2436479
[No Abstract] [Full Text] [Related]
51. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
Jonasch E; Haluska FG
Oncologist; 2001; 6(1):34-55. PubMed ID: 11161227
[TBL] [Abstract][Full Text] [Related]
52. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
53. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
54. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
55. Imatinib mesylate (STI571) for myeloid malignancies other than CML.
Krystal GW
Leuk Res; 2004 May; 28 Suppl 1():S53-9. PubMed ID: 15036942
[TBL] [Abstract][Full Text] [Related]
56. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
57. Therapy of chronic myelogenous leukemia with interferon.
Kurzrock R; Gutterman JU; Kantarjian H; Talpaz M
Cancer Invest; 1989; 7(1):83-91. PubMed ID: 2472193
[No Abstract] [Full Text] [Related]
58. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
59. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome.
Mozziconacci MJ; Sainty D; Chabannon C
Am J Hematol; 2007 Jul; 82(7):688-9. PubMed ID: 17366548
[No Abstract] [Full Text] [Related]
60. An evaluation of the cardiotoxicity of imatinib mesylate.
Ribeiro AL; Marcolino MS; Bittencourt HN; Barbosa MM; Nunes Mdo C; Xavier VF; Clementino NC
Leuk Res; 2008 Dec; 32(12):1809-14. PubMed ID: 18495246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
